Extracellular Vesicles and Cell Therapies in Regenerative Nephrology and Urology
A special issue of Cells (ISSN 2073-4409). This special issue belongs to the section "Cell Microenvironment".
Deadline for manuscript submissions: 30 June 2026 | Viewed by 584
Special Issue Editors
Interests: precision medicine; extracellular vesicles (EVs); vasculogenesis; cell transplantation therapy; stem cell transplantation
Interests: extracellular vesicles; nano-extracellular vesicles; renal diseases; nephrology; regenerative medicine
Special Issue Information
Dear Colleagues,
Extracellular vesicles (EVs) and cellular therapies are converging to redefine regenerative nephrology and urology. EVs released by renal, immune, and vascular cells carry bioactive cargo proteins, lipids, and microRNAs that orchestrate inflammation, fibrosis, tubular injury, immune modulation, and repair. Their disease-specific signatures in urine and blood enable minimally invasive diagnostics and dynamic monitoring across acute kidney injury (AKI), chronic kidney disease (CKD), diabetic kidney disease, glomerulopathies, polycystic kidney disease, obstructive uropathy, and transplant rejection. In parallel, cell-based interventions (e.g., mesenchymal stromal cells, endothelial/epithelial progenitors, iPSC-derived products, immune-modulatory cells) are advancing toward clinical use; mounting evidence suggests EVs mediate a substantial fraction of their therapeutic effects, inspiring cell-free and EV-engineered strategies with improved safety, stability, and targeting. This Special Issue invites original research, reviews, and methods papers spanning EV biology and cargo function; urinary EV biomarkers; engineered and targeted EVs; synergy between EVs, cell therapies, and biomaterials; manufacturing, characterization, and quality control (GMP readiness, potency assays); and regulatory and ethical considerations. We also particularly welcome multi-omics, single-cell/spatial approaches, imaging, and AI/ML pipelines for biomarker discovery, patient stratification, and treatment-response prediction. Our goal is to bridge mechanisms with translation and accelerate precise, scalable EV- and cell-based therapeutics for kidney health.
Dr. Amankeldi Salybekov
Dr. Ciro Tetta
Guest Editors
Manuscript Submission Information
Manuscripts should be submitted online at www.mdpi.com by registering and logging in to this website. Once you are registered, click here to go to the submission form. Manuscripts can be submitted until the deadline. All submissions that pass pre-check are peer-reviewed. Accepted papers will be published continuously in the journal (as soon as accepted) and will be listed together on the special issue website. Research articles, review articles as well as short communications are invited. For planned papers, a title and short abstract (about 250 words) can be sent to the Editorial Office for assessment.
Submitted manuscripts should not have been published previously, nor be under consideration for publication elsewhere (except conference proceedings papers). All manuscripts are thoroughly refereed through a single-blind peer-review process. A guide for authors and other relevant information for submission of manuscripts is available on the Instructions for Authors page. Cells is an international peer-reviewed open access semimonthly journal published by MDPI.
Please visit the Instructions for Authors page before submitting a manuscript. The Article Processing Charge (APC) for publication in this open access journal is 2700 CHF (Swiss Francs). Submitted papers should be well formatted and use good English. Authors may use MDPI's English editing service prior to publication or during author revisions.
Keywords
- extracellular vesicles (EVs)
- microRNA (miRNA)
- acute kidney injury (AKI)
- chronic kidney disease (CKD)
- glomerulonephritis
- kidney transplantation
- fibrosis
- mesenchymal stromal cells (MSCs)
- engineered EVs
- single-cell and spatial omics
- machine learning and artificial intelligence;
- precision nephrology
- GMP manufacturing
- regenerative medicine
- biomarkers
- artificial intelligence (AI)
Benefits of Publishing in a Special Issue
- Ease of navigation: Grouping papers by topic helps scholars navigate broad scope journals more efficiently.
- Greater discoverability: Special Issues support the reach and impact of scientific research. Articles in Special Issues are more discoverable and cited more frequently.
- Expansion of research network: Special Issues facilitate connections among authors, fostering scientific collaborations.
- External promotion: Articles in Special Issues are often promoted through the journal's social media, increasing their visibility.
- Reprint: MDPI Books provides the opportunity to republish successful Special Issues in book format, both online and in print.
Further information on MDPI's Special Issue policies can be found here.
